This 5 day workshop on global health diagnostics focuses on TB, HIV, malaria, sexually transmitted and blood borne infections (STBBIs), and selected neglected tropical diseases (NTDs). The workshop format is a mix of plenary talks interspersed with 1) rich, engaging panel discussions, 2) tech pitches from industry leaders and 3) plenty of opportunity to interact with participants who work across the spectrum of global health diagnostics. Participants will learn from a wide array of key stakeholders including product manufacturers, donors, product development partnerships, policy makers, academics, clinicians, researchers, community advocates, public health implementers and leaders from ministries of health in priority countries.
2017 Global Health Diagnostics Agenda coming soon.
2016 Global Health Diagnostics Agenda
Cédric Yansouni, MD, FRCPC, DTM&H
Assistant Professor, Division of Infectious Diseases, Department of
Medical Microbiology, McGill University
Associate Director, J.D. MacLean Centre for Tropical Diseases
Nitika Pant Pai, MD, MPH, PhD
Associate Professor, Division of Clinical Epidemiology & Infectious
Diseases, McGill University
Madhukar Pai, MD, PhD
Professor of Epidemiology, McGill University
Director, McGill Global Health Programs
Associate Director, McGill International TB Centre
Tim Amukele, MD PhD – Johns Hopkins University
Jeff Baker – JESA Consulting
David Bell, MD, PhD – Intellectual Ventures
Catharina Boehme, MD – FIND
Emmanuel Bottieau, MD, PhD – Institute of Tropical Medicine
Peter Dailey, PhD, MPH – UC Berkeley
Renuka Gadde, MBA – BD (Becton Dickinson)
David Goldfarb, PhD – University of British Columbia
Michael Greenberg, MD – Fio Corporation
Theresa Gyorkos, PhD – McGill University
Jacqueline Huh, MBA – Stop TB Partnership
Jan Jacobs, MD – Institute of Tropical Medicine
Ilesh Jani, MD, PhD – Instituto Nacional de Saude
Cassandra Kelly-Cirino, PhD – DNA Genotek
John Kim, PhD – Public Health Agency of Canada
Michael Libman, MD – McGill University
Robert Luo, MD – Roche Molecular Systems, Inc.
Greg Matlashewski, PhD – McGill University
Mark Miller, MD, FRCPC – bioMerieux
Momar Ndao, PhD – McGill University
Thomas Nutman, MD – National Institutes of Health
Rosanna Peeling, PhD – London School of Hygiene & Tropical Medicine
David Persing, MD, PhD – Cepheid
Trevor Peter, PhD – Clinton Health Access Initiative
William Rodriguez, MD – FIND
Lee Schroeder, MD PhD – University of Michigan
Marc Steben, MD – INSPQ
Andy Stewart – DNA Genotek
Rejean Thomas, MD – L’Actuel
Prashant Yadav, PhD, MBA – University of Michigan
Infectious diseases continue to pose a major threat to the health of most developing nations. The emergence and spread of infections like XDR-TB, Ebola, dengue, chikungunya, and avian influenza have highlighted the importance of effective global response to epidemic threats. Diagnosis is a critical step in effective disease care and control, but many people in developing countries do not have access to adequate initial diagnosis.
- Convene key stakeholder groups on global health diagnostics, to create a platform for information exchange and knowledge transfer.
- Inform, educate, engage and convene discussions on pertinent issues in diagnostics so as to inform the direction of future practice, policy and funding initiatives for diagnostics.
- Dissect the value chain for global health diagnostics development, current pipeline of diagnostics, market size and dynamics, policies on diagnostics, and barriers for scale-up for selected infectious diseases of global health importance across all infections.
- Debate and propose solutions for accelerating market entry for innovative diagnostics, to sustain and support manufacturers’ engagement in development of new diagnostics that address unmet global health needs.
- Debate and identify novel approaches to scale-up, including innovative business models that leverage market-based incentives.
This course appeals to a wide range of participants including:
- Policy makers and ministry officials
- Researchers, academics, and students studying global health or infectious disease
- Product developers, funders and public health agency officials
- Community advocacy groups- working in diagnostics and global health
Maximum of 150 participants.